These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33415556)

  • 1. Landmark Series: Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer.
    He J; Schulick RD; Del Chiaro M
    Ann Surg Oncol; 2021 Mar; 28(3):1514-1520. PubMed ID: 33415556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis.
    Li X; Huang J; Jiang C; Chen P; Quan Q; Jiang Q; Li S; Guo G
    Eur J Clin Pharmacol; 2023 Mar; 79(3):323-340. PubMed ID: 36576528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer: A propensity score matched analysis.
    Peng JS; Morris-Stiff G; Ali NS; Wey J; Chalikonda S; El-Hayek KM; Walsh RM
    Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):74-79. PubMed ID: 32861576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
    Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
    Oncologist; 2016 Feb; 21(2):178-87. PubMed ID: 26834159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer.
    Cho IR; Chung MJ; Bang S; Park SW; Chung JB; Song SY; Seong J; Hwang HK; Kang CM; Lee WJ; Park JY
    Pancreatology; 2013; 13(5):539-43. PubMed ID: 24075521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
    Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
    Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
    Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
    Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy in patients with borderline resectable pancreatic cancer.
    Yasuta S; Kobayashi T; Aizawa H; Takahashi S; Ikeda M; Konishi M; Kojima M; Kuno H; Uesaka K; Morinaga S; Miyamoto A; Toyama H; Takakura N; Sugimachi K; Takayama W
    BMC Cancer; 2020 Dec; 20(1):1184. PubMed ID: 33267820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
    Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
    JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current update of treatment strategies for borderline resectable pancreatic cancer: a narrative review.
    Ono A; Murakami Y; Abdel-Wahab M; Nagata Y
    J Gastrointest Oncol; 2022 Apr; 13(2):885-897. PubMed ID: 35557564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement.
    Hirono S; Kawai M; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Yamaue H
    Pancreas; 2016 Nov; 45(10):1438-1446. PubMed ID: 27088490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer.
    Kang CM; Hwang HK; Choi SH; Lee WJ
    Surg Oncol; 2013 Jun; 22(2):123-31. PubMed ID: 23518243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Multicenter Single-Arm Phase II Study Protocol.
    Miyasaka Y; Ohtsuka T; Eguchi S; Inomata M; Nishihara K; Shinchi H; Okuda K; Baba H; Nagano H; Ueki T; Noshiro H; Nakamura M;
    Int J Surg Protoc; 2021 Apr; 25(1):55-60. PubMed ID: 34013145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.
    Takahashi S; Kinoshita T; Konishi M; Gotohda N; Kato Y; Kinoshita T; Kobayashi T; Mitsunaga S; Nakachi K; Ikeda M
    J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):567-74. PubMed ID: 21331805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Meta-analysis and trial sequential analysis of randomized controlled trials.
    Hajibandeh S; Hajibandeh S; Intrator C; Hassan K; Sehmbhi M; Shah J; Mazumdar E; Kausar A; Satyadas T
    Ann Hepatobiliary Pancreat Surg; 2023 Feb; 27(1):28-39. PubMed ID: 36536501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits.
    Heinrich S; Lang H
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28933761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS).
    Bockhorn M; Uzunoglu FG; Adham M; Imrie C; Milicevic M; Sandberg AA; Asbun HJ; Bassi C; Büchler M; Charnley RM; Conlon K; Cruz LF; Dervenis C; Fingerhutt A; Friess H; Gouma DJ; Hartwig W; Lillemoe KD; Montorsi M; Neoptolemos JP; Shrikhande SV; Takaori K; Traverso W; Vashist YK; Vollmer C; Yeo CJ; Izbicki JR;
    Surgery; 2014 Jun; 155(6):977-88. PubMed ID: 24856119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of defining borderline resectable pancreatic cancer.
    Kang MJ; Jang JY; Kwon W; Kim SW
    Pancreatology; 2018 Mar; 18(2):139-145. PubMed ID: 29274720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
    Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
    Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.